Monday , February 19 2018
Home / Technology & Devices

Technology & Devices

SkylineDx and Mayo Clinic Enter Strategic Collaboration to Develop Diagnostic Tests for Melanoma

ROTTERDAM, Netherlands, Jan. 31, 2018 /PRNewswire/ — SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop …

Read More »

FDA Approves First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are …

Read More »

Ligand Enters into Worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive …

Read More »

QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Non-Small Cell Lung Cancer

Germantown, Maryland, and Hilden, Germany, January 18, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use …

Read More »

OncoSec Provides Encouraging Clinical Observations Related to Triple Negative Breast Cancer Study

SAN DIEGO, Jan. 18, 2018 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot biomarker OMS-I140 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer (TNBC). The study is …

Read More »

X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca

WALTHAM, Mass.–(BUSINESS WIRE)–Small molecule discovery specialist X-Chem, Inc. today announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company AstraZeneca. The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing …

Read More »

Adimab and Boehringer Ingelheim Enter Antibody Discovery Collaboration

LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Boehringer Ingelheim (BI). Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, …

Read More »

Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Detection of Lung Cancer Biomarkers

SAN DIEGO, Jan. 9, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the …

Read More »

Incyte and Syros Enter Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms

WILMINGTON, Del. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative …

Read More »

Adaptive Biotechnologies and Microsoft Partner to Decode the Human Immune System to Improve Disease Diagnosis

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a leader in next-generation sequencing (NGS) of T- and B-cell receptors of the adaptive immune system, announced today their partnership with Microsoft to map the genetics of the human immune system, or immunome, in order to detect cancers and other diseases in their earliest stage, when they …

Read More »